Neovascular Age-related Macular Degeneration
8 competing products in clinical development for Neovascular Age-related Macular Degeneration.
Pipeline by Phase
Phase 13
Phase 1/21
Phase 24
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | Completed | 35 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | Completed | 29 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | Completed | 29 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | Terminated | 27 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | Completed | 25 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | Completed | 25 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | Completed | 22 |